Following stocks are close to their 52-week low as at 12.49 p.m. on June 14, 2018.

The share price of Cipla surged by nearly 2 per cent in the early trade on Thursday as the company received the USFDA approval for Isoproterenol Hydrochloride injection, a generic version of Hospira Inc’s Isuprel injection.

The markets on June 14, 2018 opened down. BSE Sensex is trading at 35,518.34, down by 220.82 points and the Nifty is trading at 10,782.85, down by 73.85 points. 

Pharma major Alembic Pharmaceuticals bagged the approval of US Food and Drugs Association for its abbreviated new drug application (ANDA) for Doxycycline Hyclate capsules.

ICICI Bank received approval from its board of directors for sale of 2 per cent stake in ICICI Prudential through an offer for sale.

Overall volumes in futures & options currently stand at 73.61 lakh contracts with a turnover of Rs. 6,93,000.92 crore.

Overall volumes in futures & options currently stand at 73.61 lakh contracts with a turnover of Rs. 6,93,000.92 crore.

In the coming session, the level of 10,890 is likely to act as an immediate resistance level, followed by 10,930, while on the downside, supports are seen at the levels of 10,800, followed by 10,770. Stocks in news: HDFC Bank, Infosys, Canara Bank, Cipla, Oberoi Realty, ICICI Bank, Kansai Nerolac, Lupin and Tata Power.

Key benchmark indices are expected to open on a pessimistic note amid negative global cues. Nifty 50 index futures on the Singapore stock exchange is currently trading with a loss of 27 points at 10,818.  

In a significant development, Lupin launched its generic Tobramycin Inhalation Solution USP in the US markets on Wednesday.